Matches in SemOpenAlex for { <https://semopenalex.org/work/W2418926820> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2418926820 endingPage "22" @default.
- W2418926820 startingPage "15" @default.
- W2418926820 abstract "The purpose of the study was to evaluate the effectiveness of the long-term oral pulse therapy with high doses of alphacalcidol (1 alpha (OH)D3) in severe uremic hyperparathyroidism. 43 hemodialysis patients with at least 5-fold 1-84 PTH serum elevation were given thrice a week oral (1 alpha (OH) D3) in doses up to 5 micrograms, according to serum calcium levels (monitored weekly). The drug was given in the evenings (Group A; 18 pts) or during hemodialysis sessions (Group B; 25 pts). The dialysate calcium was reduce to 1.40-1.45 mmol/l and CaCO3 was used as a main phosphate binder in doses up to 6 g/day; 13 pts received additionally small doses of Al (OH)3 (up to 3 g/day). After one month the PTH levels decreased by 67 +/- 7.7% (p < 0.001), while serum total calcium increased by 0.27 < or = 0.05 mmol/l. The parathyroid activity suppression progressed to 81 +/- 6.9% serum PTH reduction after 4 months and 74 +/- 6.1% fall after 8 months. Only 3 pts occurred to be non-responders; in 19 pts PTH levels normalized. A decrease of serum hydroxyproline and alkaline phosphatase with its bone isoenzyme activity was also observed with a direct correlation between those changes and parathyroid suppression. (1 alpha (OH) D3) dose at first month of therapy was 3.4 +/- 0.15 micrograms, but it was successively reduced because of hypercalcemia to a final dose of 2.2 +/- 0.22 micrograms. The frequency of hyperkalcemia was 7.6%; no difference between Group A and group B was noted. We conclude that oral (1 alpha (OH)D3) pulse therapy is very effective in the long-term parathyroid activity suppression in hemodialysis patients with severe hyperparathyroidism. To avoid dangerous hypercalcemia and relative hypoparathyroidism serum PTH and calcium levels should be carefully monitored." @default.
- W2418926820 created "2016-06-24" @default.
- W2418926820 creator A5006063464 @default.
- W2418926820 creator A5006542674 @default.
- W2418926820 creator A5012096302 @default.
- W2418926820 creator A5012639529 @default.
- W2418926820 creator A5034560347 @default.
- W2418926820 creator A5067093457 @default.
- W2418926820 creator A5079714504 @default.
- W2418926820 date "1996-07-01" @default.
- W2418926820 modified "2023-09-27" @default.
- W2418926820 title "[Long-term treatment with large doses of alphacalicidol in secondary hyperparathyroidism of patients dialyzed for end stage renal failure]." @default.
- W2418926820 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8966141" @default.
- W2418926820 hasPublicationYear "1996" @default.
- W2418926820 type Work @default.
- W2418926820 sameAs 2418926820 @default.
- W2418926820 citedByCount "0" @default.
- W2418926820 crossrefType "journal-article" @default.
- W2418926820 hasAuthorship W2418926820A5006063464 @default.
- W2418926820 hasAuthorship W2418926820A5006542674 @default.
- W2418926820 hasAuthorship W2418926820A5012096302 @default.
- W2418926820 hasAuthorship W2418926820A5012639529 @default.
- W2418926820 hasAuthorship W2418926820A5034560347 @default.
- W2418926820 hasAuthorship W2418926820A5067093457 @default.
- W2418926820 hasAuthorship W2418926820A5079714504 @default.
- W2418926820 hasConcept C126322002 @default.
- W2418926820 hasConcept C126894567 @default.
- W2418926820 hasConcept C134018914 @default.
- W2418926820 hasConcept C160160445 @default.
- W2418926820 hasConcept C181199279 @default.
- W2418926820 hasConcept C185592680 @default.
- W2418926820 hasConcept C2775945674 @default.
- W2418926820 hasConcept C2776635150 @default.
- W2418926820 hasConcept C2778063415 @default.
- W2418926820 hasConcept C2778838027 @default.
- W2418926820 hasConcept C2779797417 @default.
- W2418926820 hasConcept C2781208988 @default.
- W2418926820 hasConcept C519063684 @default.
- W2418926820 hasConcept C55493867 @default.
- W2418926820 hasConcept C71924100 @default.
- W2418926820 hasConcept C90924648 @default.
- W2418926820 hasConceptScore W2418926820C126322002 @default.
- W2418926820 hasConceptScore W2418926820C126894567 @default.
- W2418926820 hasConceptScore W2418926820C134018914 @default.
- W2418926820 hasConceptScore W2418926820C160160445 @default.
- W2418926820 hasConceptScore W2418926820C181199279 @default.
- W2418926820 hasConceptScore W2418926820C185592680 @default.
- W2418926820 hasConceptScore W2418926820C2775945674 @default.
- W2418926820 hasConceptScore W2418926820C2776635150 @default.
- W2418926820 hasConceptScore W2418926820C2778063415 @default.
- W2418926820 hasConceptScore W2418926820C2778838027 @default.
- W2418926820 hasConceptScore W2418926820C2779797417 @default.
- W2418926820 hasConceptScore W2418926820C2781208988 @default.
- W2418926820 hasConceptScore W2418926820C519063684 @default.
- W2418926820 hasConceptScore W2418926820C55493867 @default.
- W2418926820 hasConceptScore W2418926820C71924100 @default.
- W2418926820 hasConceptScore W2418926820C90924648 @default.
- W2418926820 hasIssue "1" @default.
- W2418926820 hasLocation W24189268201 @default.
- W2418926820 hasOpenAccess W2418926820 @default.
- W2418926820 hasPrimaryLocation W24189268201 @default.
- W2418926820 hasRelatedWork W2054384551 @default.
- W2418926820 hasRelatedWork W2073714215 @default.
- W2418926820 hasRelatedWork W2082708611 @default.
- W2418926820 hasRelatedWork W2153963350 @default.
- W2418926820 hasRelatedWork W2161501577 @default.
- W2418926820 hasRelatedWork W2213868530 @default.
- W2418926820 hasRelatedWork W2410277139 @default.
- W2418926820 hasRelatedWork W2416442364 @default.
- W2418926820 hasRelatedWork W2419165074 @default.
- W2418926820 hasRelatedWork W92514502 @default.
- W2418926820 hasVolume "96" @default.
- W2418926820 isParatext "false" @default.
- W2418926820 isRetracted "false" @default.
- W2418926820 magId "2418926820" @default.
- W2418926820 workType "article" @default.